Journal Home
Search for

Volume 27, Issue 1, Pages 51-56 (January 2003)

1 of 16 View next.

Cyclic AMP induces activation of extracellular signal-regulated kinases in HL-60 cells: role in cAMP-induced differentiation

Young-Jin Choa, Ju-Young Kima, Seong-Whan Jeongb, Sang Bok Leea, Ok Nyu KimaCorresponding Author Informationemail address

Received 20 July 2001; accepted 11 March 2002.

Abstract 

It is well known that elevated intracellular cAMP induces growth arrest and the differentiation of HL-60 cells to neutrophil-like cells. The present study was designed to assess the regulation of the extracellular signal-regulated kinase (ERK) pathway by cAMP and its association with differentiation in HL-60 cells. We found that 8-bromoadenosine-3′,5′-cyclic-monophosphate (8Br-cAMP)-induced the activation of ERK and mitogen-activated protein kinase (MEK), but inhibited B-Raf kinase via a protein kinase A (PKA)-mediated mechanism. Prolonged exposure to 8Br-cAMP increased the phorbol 12-myristate 13-acetate (TPA)-stimulated superoxide generation and CD14 expression that characterize the differentiation phenotype, which was blocked by MEK-1 inhibitor. These data suggest that cAMP-induced ERK activation is essential for the differentiation of HL-60 cells, independently of B-Raf.

Article Outline

Abstract

1. Introduction

2. Materials and methods

2.1. Reagents

2.2. Cell culture and induction of differentiation

2.3. Western blot analysis

2.4. Immunoprecipitation and B-Raf kinase assay

2.5. Chemiluminescence assay

2.6. FACS analysis for CD14 expression

3. Results

3.1. Cyclic AMP induces ERK activation

3.2. Upstream components of the ERK signaling pathway

3.3. cAMP-induced ERK activation induces the differentiation of HL-60 cells

4. Discussion

Acknowledgment

References

Copyright

1. Introduction 

return to Article Outline

Differentiation of human promyelocytic HL-60 leukemia cells can be promoted by a number of agents that increase intracellular cAMP either by activators of adenylyl cyclase, inhibitors of cyclic nucleotide phosphodiesterase, or cell-permeable forms of cAMP [1], [2], [3], [4]. Cessation of growth and the morphological characteristics of myelocytes and metamyelocytes characterize the differentiated phenotype. Functionally, these cells generate superoxide, and express the receptors for complement and chemotactic formyl peptide. The mechanisms by which these agents act are not fully understood. However, activation of ERK may be involved because a rapid increase in the phosphorylation of ERK has been induced in HL-60 cells by a wide range of differentiation-inducing agents, including by TPA, 1,25-dihydroxyvitamin D3, and retinoic acid [5], [6], [7].

Activation of ERK isoforms typically occurs via a kinase-mediated signaling cascade consisting of the linear sequential activation of Ras, Raf, and MEK. Elevated levels of cAMP inhibit the activation of the ERK pathway in many cell types via the PKA-mediated inhibition of the interaction between Ras and the downstream kinase Raf-1 [8]. However, in pheochromocytoma (PC12) cells, increased intracellular cAMP levels stimulate ERK activity. ERK activation occurs through the activation of the Ras-related small G protein, Rap1, which activates B-Raf [9]. The cAMP-induced activation of Rap1 may occur through guanine–nucleotide exchange factors that are regulated either directly by cAMP binding or indirectly by a mechanism requiring PKA phosphorylation [10], [11]. These findings suggest that cAMP can elicit differential effects on the ERK pathway in a cell type-specific manner. This prompted us to examine the effects of cAMP on the ERK pathway in the cAMP-induced differentiation of HL-60 cells. We show that ERK was activated when the cells were treated with a membrane-permeable form of cAMP or an adenylyl cyclase activator. In contrast, treatment with cAMP inhibited B-Raf activity, suggesting a B-Raf-independent mechanism for ERK activation. Furthermore, we demonstrate that cAMP-induced ERK activation is essential for the differentiation of HL-60 cells.

2. Materials and methods 

return to Article Outline

2.1. Reagents 

8Br-cAMP was purchased from Boehringer Mannheim (Indianapolis, IN); PD98059 and forskolin were from Calbiochem-Novabiochem (San Diego, CA); anti-phosphorylated ERK, anti-ERK, and anti-MEK antibodies were from New England BioLabs (Beverly, MA); anti-B-Raf antibody (#06-532) and inactive MEK-1-GST for the kinase assay were from Upstate Biotechnology (Lake Placid, NY); anti-B-Raf antibody for Western blotting was from Santa Cruz Biotechnology (Santa Cruz, CA); luminol and TPA were purchased from Sigma (St. Louis, MO). All other reagents were of the highest purity available.

2.2. Cell culture and induction of differentiation 

HL-60 cells were purchased from the American Type Culture Collection (Rockville, MD). Cells were maintained in RPMI 1640 medium supplemented with 15% fetal bovine serum (FBS; HyClone, Logan, UT). In experiments, cells growing logarithmically were serum-starved for 24h in medium containing 0.5% FBS. To induce differentiation, cells in logarithmic phase were seeded at 5×105/ml and treated with 1mM 8Br-cAMP for 48h. To test the role of ERK activation in differentiation, 20μM PD98059 was added to the culture 30min before treatment with 8Br-cAMP.

2.3. Western blot analysis 

Cells were harvested and lysed in buffer containing 25mM HEPES (pH 8.0), 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 137mM NaCl, 2mM EDTA, 1mM Na3VO4, 1mM NaF, 1mM phenylmethylsulfonyl fluoride, 5μg/ml aprotinin, and 5μg/ml leupeptin. Insoluble materials were removed by centrifugation for 10min at 15,000×g. Protein concentrations were measured by BCA protein assay reagent (Pierce, Rockford, IL). Proteins (40mg) were separated by 9% SDS–polyacrylamide gel electrophoresis (SDS–PAGE) under reducing conditions, and Western blotting was performed using the methods of Choi et al. [12]. Immune complexes were detected by chemiluminescence (SuperSignal WestDura, Pierce) under the conditions recommended by the supplier.

2.4. Immunoprecipitation and B-Raf kinase assay 

B-Raf kinase was assayed with the B-Raf Immunoprecipitation Kinase Cascade Assay Kit (Upstate Biotechnology) following the manufacturer’s protocol. B-Raf was immunoprecipitated using anti-B-Raf antibody and protein G–agarose beads. The beads were washed, then incubated with 1μg recombinant MEK-1 and 10μCi γ-[] ATP in assay buffer (20mM MOPS (pH 7.2), 25mM β-glycerophosphate, 5mM EGTA, 1mM Na3VO4, 1mM dithiothreitol) for 30min at 30°C. Reaction products were separated by SDS–PAGE, and the dried gel exposed to X-ray film or analyzed with a BioImaging BAS2500 Analyzer (Fuji, Tokyo, Japan).

2.5. Chemiluminescence assay 

Superoxide production by HL-60 cells was measured by luminol-enhanced chemiluminescence and recorded with a luminometer (Bio-Rad, Hercules, CA), using the methods of Cho et al. [13]. Cells were washed twice with Dulbecco’s phosphate-buffered saline (PBS, 137mM NaCl, 2.7mM KCl, 8mM Na2HPO4, 1.5mM KH2PO4, 0.9mM CaCl2, 0.49mM MgCl2, 5.6mM d-glucose, 0.33mM sodium pyruvate) containing 0.1% bovine serum albumin and resuspended at 2×106 cells per ml. A 300μl aliquot of cells and 100μl PBS containing luminol (100μM) were added to the cuvettes of the luminometer and allowed to equilibrate for 5min at 37°C before stimulation with TPA (final concentration, 3μM). The intensity of the developing chemiluminescence was measured for 30min at 37°C and the results were presented graphically with time units on the abscissa and light intensity units (mV) on the ordinate. The values (in V) for peak height per 1×105 viable cells were evaluated. Data are presented as mean±standard deviation (S.D.). Statistical significance was determined by Student’s t-test.

2.6. FACS analysis for CD14 expression 

CD14 expression was measured using a fluorescence-activated cell sorter (FACS) with the methods of Cho et al. [13]. Cells (1×106) resuspended in PBS containing 0.1% sodium azide and 5% FBS were incubated at 4°C for 30min with 1μg FITC-conjugated anti-CD14 antibody (BioSource, Camarillo, CA). The cells were then washed twice and fixed with 2% formaldehyde in PBS. Fluorescence was analyzed with a FACSVantage flow cytometer using Cellquest software (Becton Dickinson, Bedford, MA).

3. Results 

return to Article Outline

3.1. Cyclic AMP induces ERK activation 

To assess the involvement of ERK activation in the cAMP-induced differentiation of HL-60 cells, we analyzed the phosphorylation state of ERK 30min after the addition of various concentrations of 8Br-cAMP. An antibody specific for the doubly-phosphorylated form of ERK was used to probe the Western blot (Fig. 1A, upper half), and the equivalence of protein per lane was demonstrated with an antibody that recognizes ERK-2 irrespective of its phosphorylation state (Fig. 1A, lower half). The phosphorylation of endogenous ERK in HL-60 cells increased in a dose-dependent manner, up to 3mM 8Br-cAMP. A time-course analysis showed that cAMP-induced the rapid activation of ERK within 5min, and this was sustained for up to 6h (Fig. 1B). To confirm that the activation of ERK was cAMP-mediated, we tested the effects of another intracellular cAMP-elevating agent, forskolin, which stimulates adenylyl cyclase. Consistent with the findings after 8Br-cAMP treatment, 10μM forskolin stimulated ERK phosphorylation (Fig. 1C).


View full-size image.

Fig. 1. 8Br-cAMP induces the activation of ERK in HL-60 cells. (A) Cells were cultured in medium containing 0.5% FBS for 24h before addition of the indicated concentrations of 8Br-cAMP for 30min. The cell lysates were analyzed by Western blot using either an antibody specific for active ERK-1 and ERK-2 doubly-phosphorylated at Thr202/Tyr204 (upper panel), or with anti-ERK antibody to control for protein loading (lower panel). (B) The kinetics of cAMP-induced ERK phosphorylation were observed by incubating the cells with 1mM 8Br-cAMP for the periods indicated (0–6h). (C) The effect of 20μM forskolin on the phosphorylation of ERKs for the periods indicated (0–1h).


3.2. Upstream components of the ERK signaling pathway 

To identify the upstream signal, we next examined the activation of MEK 30min after the addition of 8Br-cAMP. The phosphorylation of MEK increased in a dose-dependent manner with 8Br-cAMP treatment (Fig. 2A). Moreover, PD98059, a MEK-1 inhibitor, completely blocked ERK phosphorylation, indicating that ERK activation is mediated by MEK (Fig. 2B).


View full-size image.

Fig. 2. 8Br-cAMP-induced activation of ERK is mediated by MEK in HL-60 cells. (A) Dose-dependent activation of MEK by 8Br-cAMP in HL-60 cells. Quiescent cells were treated for 30min with the concentrations of 8Br-cAMP indicated. The blots were probed with an antibody specific for active MEK, phosphorylated at Ser217/221 (upper panel), and anti-MEK antibody to control for loading (lower panel). (B) Effect of MEK-1 inhibitor on the 8Br-cAMP-induced activation of ERK. Quiescent cells were treated with 10μM PD98059 for 30min before 1mM 8Br-cAMP was added for 30min. The blots were probed with an antibody specific for phosphorylated ERK (upper panel), or with anti-ERK antibody to control for protein loading (lower panel).


In B-Raf-expressing cells, ERK activation by cAMP has been observed and has been attributed to Rap1 activation, with the subsequent activation of B-Raf. Previous studies have suggested that Rap1 may be important in the differentiation of HL-60 cells [14], [15], [16]. For example, cGMP induces the activation of Rap1 in parental HL-60 cells, but not in variant cells which are resistant to cGMP-induced differentiation [17]. Therefore, we examined whether B-Raf is the molecule upstream from MEK activation. In contrast to the finding that cAMP activates MEK and ERK, B-Raf activity was inhibited by 8Br-cAMP (Fig. 3A). Pretreatment with H89, a PKA inhibitor, blocked the cAMP-mediated inhibition of B-Raf (Fig. 3B). These results indicate that B-Raf activity is negatively regulated by cAMP via a PKA-dependent mechanism.


View full-size image.

Fig. 3. 8Br-cAMP inhibits B-Raf kinase activity in HL-60 cells. (A) The negative regulation of B-Raf kinase by 8Br-cAMP. Quiescent cells were treated with 1mM 8Br-cAMP for the periods indicated (0–6h). Cell lysates were immunoprecipitated using a B-Raf-specific antibody that recognizes residues 10–22 of human B-Raf kinase. Immunoprecipitates were incubated in the presence of MEK-1 and γ-[] ATP for 30min and subjected to SDS–PAGE and autoradiography to assess MEK phosphorylation (upper panel). The lysates were analyzed in parallel with anti-B-Raf antibody (lower panel). (B) Effect of PKA inhibitor on the inhibition of B-Raf kinase by 8Br-cAMP. H89 (10μM) was added to cell cultures 30min before treatment with 1mM 8Br-cAMP for 30min. Cell lysates were immunoprecipitated and assayed for B-Raf kinase protein, as described.


3.3. cAMP-induced ERK activation induces the differentiation of HL-60 cells 

We next investigated whether cAMP-mediated ERK activation plays an essential role in the process of differentiation. The functional phenotype of differentiated HL-60 cells was identified by their inducible oxidative metabolism, a characteristic of mature myelomonocytic cells. Cells cultured in the presence of 8Br-cAMP for 48h generated 4.5-fold more TPA-stimulated superoxide than cells cultured in the absence of 8Br-cAMP. This increase was significantly inhibited, to 1.7-fold, by pretreatment with PD98059 (Fig. 4). Flow cytometric analysis of CD14 expression demonstrated that the proportion of CD14 antigen-positive cells increased from 4.2 to 63.5% when cultured in the presence of 8Br-cAMP (Fig. 5). Moreover, the cAMP-induced expression of CD14 antigen was inhibited from 63.5 to 35.0% by treatment with PD98059 (Fig. 5). These results clearly show that cAMP-induced ERK activation plays a role in the differentiation of HL-60 cells.


View full-size image.

Fig. 4. TPA stimulates superoxide generation in HL-60 cells pretreated with 8Br-cAMP. Cells cultured in medium containing 1mM 8Br-cAMP with or without 20μM PD98059 for 2 days were stimulated with 3μM TPA. Maximal generation of luminol-enhanced chemiluminescence was measured as described in Section 2. The data are presented as the mean±S.D. of four independent experiments; P<0.05, compared with cells treated with 8Br-cAMP only.



View full-size image.

Fig. 5. 8Br-cAMP induces CD14 expression in HL-60 cells. Cells were cultured in medium containing 1mM 8Br-cAMP with or without 20μM PD98059 for 2 days. The cells were probed with FITC-conjugated anti-CD14 antibody, and the fluorescence was analyzed as described in Section 2. Percentages of cells positive for CD14 are indicated.


4. Discussion 

return to Article Outline

In the present study, we have demonstrated that exposure of HL-60 cells to a cell-permeable form of cAMP or to a cAMP-elevating agent induced a sustained activation of ERK, leading to the differentiation of the cells. HL-60 cells can be differentiated by one of several pathways in response to a number of differentiation-inducing agents. For example, retinoic acid induces myeloid differentiation, whereas TPA and 1,25-dihydroxyvitamin D3 induce differentiation into a monocyte/macrophage lineage. In both cases, the activation of ERK has been observed as an early event in the differentiation processes [5], [6], [7]. From the data presented here and from previous findings, it can be postulated that ERK activation in HL-60 cells may function as a lineage-independent component of the differentiation process.

It is now well established that in B-Raf-expressing cells, the elevation of intracellular cAMP levels can activate ERK via the Rap1/B-Raf pathway. Previous work has shown that Rap1 is activated through a cAMP-regulated guanine–nucleotide exchange factor when HL-60 cells are treated with membrane-permeable cAMP analogs [17]. Furthermore, activation of Rap1 and B-Raf has been shown to be necessary for the cAMP-induced ERK activation that induces the differentiation of PC12 cells [18]. Therefore, the Rap1/B-Raf pathway may be a plausible mechanism to explain cAMP-induced ERK activation in HL-60 cells. However, our data show that treatment with 8Br-cAMP resulted in the inhibition of B-Raf activity in a PKA-mediated manner. This negative regulation has been shown in a previous study in which cAMP inhibited B-Raf activity in C6 glioma and NB2A neuroblastoma cells, whereas cAMP-activated Rap1 [19]. In that study, it was proposed that B-Raf activation by Rap1 may require an additional factor, a 14-3-3 protein that may protect B-Raf from PKA-mediated inhibition. Further study is required to confirm whether HL-60 cells are similar to glioma and neuroblastoma cells in these aspects of the regulation of B-Raf activation.

It is interesting that the duration of cAMP-induced ERK activation was relatively long, remaining elevated for at least 6h. In contrast, epidermal growth factor- and fetal calf serum-induced ERK activation is terminated rapidly, within 30min of treatment (data not shown). This is in agreement with findings that prolonged activation of ERK can cause growth arrest and differentiation, whereas transient activation promotes proliferation [20], [21].

Although the mechanism by which cAMP induces ERK activation is not clear, our results identify a link between cAMP and ERK activation that leads to the differentiation of HL-60 cells even though cAMP inhibits B-Raf activity. Further study to generalize the role of ERK activation by cAMP in the induction of promyelocytic differentiation should be undertaken with another type of promyelocytic leukemic cell, such as NB-4.

Acknowledgements 

return to Article Outline

We wish to acknowledge the financial support of the Catholic Medical Center Research Foundation. Y.-J. Cho provided the concept, design, collected the data, analyzed the data, drafted the manuscript, provided critical revision, gave final approval, and provided funding for the project. J.-Y. Kim assembled the data and assisted with the analysis, and gave final approval. S.-W. Jeong collected, assembled the data, assisted with data analysis and the drafting of the paper and the revision and gave final approval. S.B. Lee provided administrative support, obtained funding, and gave final approval. O.N. Kim contributed to the concept and design, data analysis, drafting and revision of the manuscript, provided some of the funding, and gave final approval.

References 

return to Article Outline

[1]. [1] Nonaka T, Mio M, Doi M, Tasaka K. Histamine-induced differentiation of HL-60 cells. Biochem. Pharmacol. 1992;44:1115–1121. MEDLINE | CrossRef

[2]. [2] Jiang L, Foster FM, Ward P, Tasevski V, Luttrell BM, Conigrave AD. Extracellular ATP triggers cyclic AMP-dependent differentiation of HL-60 cells. Biochem. Biophys. Res. Commun. 1997;232:626–630. CrossRef

[3]. [3] Bang BE, Ericsen C, Aarbakke J. Effects of cAMP and cGMP elevating agents on HL-60 cell differentiation. Pharmacol. Toxicol. 1994;75:108–112. MEDLINE | CrossRef

[4]. [4] Chaplinski TJ, Niedel JE. Cyclic nucleotide-induced maturation of human promyelocytic leukemia cells. J. Clin. Invest. 1982;70:953–964. MEDLINE | CrossRef

[5]. [5] Das D, Pintucci G, Stern A. MAPK-dependent expression of p21WAF and p27kip1 in PMA-induced differentiation of HL-60 cells. FEBS Lett. 2000;472:50–52. Abstract | Full Text | Full-Text PDF (100 KB) | CrossRef

[6]. [6] Marcinkowska E, Widlocha A, Radzikowski C. 1,25-Dihydroxyvitamin D3-induced activation and subsequent nuclear translocation of MAPK is upstream regulated by PKC in HL-60 cells. Biochem. Biophys. Res. Commun. 1997;241:419–426. CrossRef

[7]. [7] Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid-induced mitogen-activated protein (MAP)/extracellular-signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res. 1998;58:3163–3172. MEDLINE

[8]. [8] Häfner S, Adler HS, Mischak H, Janosch P, Heidecker G, Wolfman A, et al.  Mechanism of inhibition of Raf-1 by protein kinase A. Mol. Cell. Biol. 1994;14:6696–6703. MEDLINE

[9]. [9] Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell. 1997;89:73–82. MEDLINE | CrossRef

[10]. [10] de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, et al.  Epac is a Rap1 guanine–nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396:474–477. MEDLINE | CrossRef

[11]. [11] Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, et al.  A family of cAMP-binding proteins that directly activate Rap1. Science. 1998;282:2275–2279. MEDLINE | CrossRef

[12]. [12] Choi JW, Cho Y-J, Cha SH, Lee KH, Lee SB. Distributional patterns of phospholipase C isozymes in heart and brain of spontaneously hypertensive rats. Korean J. Physiol. Pharmacol. 1997;1:385–392.

[13]. [13] Cho Y-J, Ahn WS, Cha SH, Lee KH, Kim WI, Chung MH. Hydroxyl radical-mediated commitment of HL-60 cells to differentiation: modulation of differentiation process by phospholipase inhibitors. Korean J. Physiol. Pharmacol. 1998;2:369–376.

[14]. [14] Yamashiro S, Takayama K, Shiku H, Furukawa K. Up-regulation of small GTP-binding proteins smg P21A and ras P21S during TPA-induced differentiation of human leukemia cell lines. Leuk. Res. 1993;17:129–136. MEDLINE | CrossRef

[15]. [15] Kurachi H, Wada Y, Tsukamoto N, Maeda M, Kubota H, Hattori M, et al.  Human SPA-1 gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rap1 and Rap2. J. Biol. Chem. 1997;272:28081–28088. MEDLINE | CrossRef

[16]. [16] Scheele JS, Pilz RB, von Lintig FC, Boss GR. Deficient post-translational processing of Rap1A in variant HL-60 cells. Oncogene. 1998;17:2211–2223. MEDLINE

[17]. [17] von Lintig FC, Pilz RB, Boss GR. Quantitative determination of Rap1 activation in cyclic nucleotide-treated HL-60 leukemic cells: lack of Rap1 activation in variant cells. Oncogene. 2000;19:4029–4034. MEDLINE | CrossRef

[18]. [18] Yao H, York RD, Misra-Press A, Carr DW, Stork PJ. The cyclic adenosine monophosphate-dependent protein kinase (PKA) is required for the sustained activation of mitogen-activated kinases and gene expression by nerve growth factor. J. Biol. Chem. 1998;273:8240–8247. MEDLINE | CrossRef

[19]. [19] Qiu W, Zhuang S, Lintig FC, Boss GR, Pilz RB. Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins. J. Biol. Chem. 2000;275:31921–31929. MEDLINE | CrossRef

[20]. [20] Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular-signal-regulated kinase activation. Cell. 1995;80:179–185. MEDLINE | CrossRef

[21]. [21] Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 1992;288:351–355.

a Department of Pharmacology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, South Korea

b Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Corresponding Author InformationCorresponding author. Tel.: +82-2-590-1202; fax: +82-2-536-2485.

PII: S0145-2126(02)00057-7

1 of 16 View next.